Poor tolerability of GLP-1 weight problems medicine leads many sufferers to cease taking them, leading to gaining again the load that was misplaced. Some drug corporations are attempting to develop different approaches that would function upkeep therapies following preliminary remedy with GLP-1 injections, and Response Prescription drugs now has encouraging mid-stage medical knowledge constructing the case for its tablet.
The Response drug, RDX-002, is an oral small molecule designed to inhibit a goal known as intestinal microsomal triglyceride switch protein (iMTP). The Falls Church, Virginia-based biotech says this method reduces the uptake of triglycerides (fat) and ldl cholesterol by the physique. Consequently, the physique takes in fewer energy.
Response evaluated RDX-002, taken as a twice-daily tablet, in a Section 2 take a look at that enrolled 68 contributors who had stopped or had been keen to discontinue the Novo Nordisk GLP-1 drug Wegovy or the Eli Lilly GLP-1 and GIP receptor agonist Zepbound. The primary objective was to measure the change in triglyceride ranges, in comparison with placebo, after 12 weeks. Secondary objectives embody measuring the change in physique weight and levels of cholesterol.
In accordance with outcomes launched Wednesday, Response’s drug let to statistically vital reductions in fats ranges within the blood after consuming. Moreover, outcomes at 12 weeks confirmed these reductions had been additionally related to discount in weight regain in comparison with a placebo. The startup mentioned RDX-002 was typically well-tolerated, characterizing opposed occasions as largely mild-to-moderate gastrointestinal results. No severe opposed occasions had been reported. The corporate mentioned full Section 2 knowledge will likely be introduced at an upcoming scientific assembly.
RDX-002 was found and initially developed by Floor Logix, a biotech that was acquired by Kadmon Prescription drugs. In 2021, Sanofi paid $1.9 billion to accumulate Kadmon, a deal centered primarily on Rezurocka ROCK2 inhibitor that reached the market as a remedy for persistent graft-versus-host illness. Response licensed world rights to RDX-002 from Sanofi. In accordance with Response’s web site, firm co-founder and Chief Scientific Officer Paul Sweetnam led the invention of RDX-002 at Floor Logix. Response introduced an $8 million Sequence A financing in 2022.
The lead indication for RDX-002 is addressing weight acquire from antipsychotics, a typical facet impact of those medicines. A separate Section 2 program is ongoing on this indication. However serving to sufferers keep weight reduction following GLP-1 remedy opens up one other alternative for the biotech.
“By focusing on key pathways concerned in metabolic regulation, we goal to offer a sturdy, well-tolerated resolution that helps long-term weight administration and cardiometabolic well being,” Response CEO Eric Keller mentioned in a ready assertion. “We stay dedicated to advancing the event of RDX-002 in our lead indication — antipsychotic-induced weight acquire (AIWG) — focusing on a extremely metabolically susceptible inhabitants, in addition to exploring its potential in different areas with vital unmet metabolic want.”
Picture: Peter Dazeley, Getty Photos
